Showing results (781-790 of 4,513) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|June 5, 2019
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancerFrancesco Saverio Mennini, Andrea Marcellusi, Gianluca Fabiano, et al.
Future Oncology (London, England)|June 26, 2019
Preoperative high c-reactive protein/albumin ratio is a poor prognostic factor of oral squamous cell carcinomaQiuju Wang, Xiaoyu Song, Yanzhen Zhao, et al.
Future Oncology (London, England)|July 5, 2019
Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysisShao-Wu Jing, Jian-Jun Qin, Qing Liu, et al.
Future Oncology (London, England)|October 21, 2021
Urothelial carcinoma in COVID-19: lessons from a pandemic and their impact on clinical practiceGeorges Abi Tayeh, Nour Khalil, Marwan Alkassis, et al.
Future Oncology (London, England)|September 28, 2021
CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusionMarco Boeri, Anna G Purdum, Jessie Sutphin, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
Future Oncology (London, England)|October 18, 2019
Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancerJohn Fp Bridges, Marie de la Cruz, Melissa Pavilack, et al.
Future Oncology (London, England)|March 11, 2022
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Caroline Robert, et al.
Future Oncology (London, England)|March 1, 2022
Androgen receptor expression and its prognostic value in T1N0 luminal/HER2- breast cancerWenjing Zhong, Jiarong Yi, Haoming Wu, et al.
Future Oncology (London, England)|March 31, 2022
Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropeniaPaul Cornes, John Kelton, Rongzhe Liu, et al.
Pageof 452